GlassScriptPhysician profile
Carmen Cheng
NPI 1508322587
$17,168.24
in general payments reported to CMS, 2019-2025
47 companies · $4,549 in 2025
The $4,549 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,067 · 2022: $2,994 · 2023: $3,300 · 2024: $3,258 · 2025: $4,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,006 · Travel and Lodging: $1,903 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,005.54 |
| Travel and Lodging | $1,902.66 |
| Education | $198.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,290.58 | 2021-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Collegium Pharmaceutical, INC. | $2,090.73 | 2021-2025 | Xtampza |
| Vertos Medical, INC. | $2,000.01 | 2021-2024 | Mild Device Kit |
| Scilex Pharmaceuticals INC. | $1,321.75 | 2021-2025 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,152.39 | 2021-2025 | Relistor |
| Abbott Laboratories | $1,050.52 | 2021-2025 | Octrode, Eterna, Freestyle Libre 3 |
| Abbvie INC. | $821.11 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $532.29 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Valinor Pharma, LLC | $493.38 | 2023-2025 | Movantik |
| Ibsa Pharma INC. | $335.01 | 2023-2024 | Tirosint, Licart, Tirosint |
| Medtronic, INC. | $243.37 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Averitas Pharma INC. | $236.14 | 2023-2025 | Qutenza |
| Pfizer INC. | $188.26 | 2023-2025 | |
| Spinal Simplicity, LLC | $179.28 | 2025 | Ha Minuteman G3-R |
| Vertex Pharmaceuticals Incorporated | $162.59 | 2024-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.